Light chain (AL) amyloidosis is a rare systemic disease caused by monoclonal immunoglobulin light chains with abnormal folding that aggregate into fibrils, which deposit in extracellular tissues. This process leads to cytotoxicity and organ dysfunction. Cardiac involvement is the main prognostic determinant and requires a multidisciplinary management approach. In recent years, the treatment of AL amyloidosis has significantly evolved with the introduction of innovative agents such as proteasome inhibitors, immunomodulators, and monoclonal antibodies like daratumumab, which has shown a favorable impact on hematological outcomes and organ function. The daratumumab-CyBorD regimen is currently the standard first-line therapeutic option. The therapy is tailored based on the stage of cardiac and renal damage, aim ing for a complete hematological and organ response. The management of cardiac involvement, including aortic stenosis, atrial fibrillation, thromboembolic risk, conduction disorders, arrhythmias, and heart failure, plays a crucial role in prognosis. An integrated multidisciplinary approach in specialized centers experienced in the disease is essential to optimize clinical outcomes.

Amiloidosi cardiaca da catene leggere: gestione multidisciplinare e innovazioni terapeutiche. Documento di consenso SIC/ANMCO della Rete Italiana dell’Amiloidosi Cardiaca (RIAC) / Aimo, A., Vergaro, G., Castiglione, V., Ferrari Chen, Y.F., Porcari, A., Canepa, M., Chimenti, C., Di Lenarda, A., Oliva, F., Colivicchi, F., Indolfi, C., Perrone Filardi, P., Cipriani, A., Longhi, S., Cappelli, F., Musca, F., Iacoviello, M., Limongelli, G., Perfetto, F., Merlini, G., et al.. - In: GIORNALE ITALIANO DI CARDIOLOGIA. - ISSN 1827-6806. - 27:2(2026), pp. 141-153. [10.1714/4636.46471]

Amiloidosi cardiaca da catene leggere: gestione multidisciplinare e innovazioni terapeutiche. Documento di consenso SIC/ANMCO della Rete Italiana dell’Amiloidosi Cardiaca (RIAC)

Chimenti, Cristina;
2026

Abstract

Light chain (AL) amyloidosis is a rare systemic disease caused by monoclonal immunoglobulin light chains with abnormal folding that aggregate into fibrils, which deposit in extracellular tissues. This process leads to cytotoxicity and organ dysfunction. Cardiac involvement is the main prognostic determinant and requires a multidisciplinary management approach. In recent years, the treatment of AL amyloidosis has significantly evolved with the introduction of innovative agents such as proteasome inhibitors, immunomodulators, and monoclonal antibodies like daratumumab, which has shown a favorable impact on hematological outcomes and organ function. The daratumumab-CyBorD regimen is currently the standard first-line therapeutic option. The therapy is tailored based on the stage of cardiac and renal damage, aim ing for a complete hematological and organ response. The management of cardiac involvement, including aortic stenosis, atrial fibrillation, thromboembolic risk, conduction disorders, arrhythmias, and heart failure, plays a crucial role in prognosis. An integrated multidisciplinary approach in specialized centers experienced in the disease is essential to optimize clinical outcomes.
2026
Light chain amyloidosis; Outcome; Plasma cells; Staging; Treatment
01 Pubblicazione su rivista::01a Articolo in rivista
Amiloidosi cardiaca da catene leggere: gestione multidisciplinare e innovazioni terapeutiche. Documento di consenso SIC/ANMCO della Rete Italiana dell’Amiloidosi Cardiaca (RIAC) / Aimo, A., Vergaro, G., Castiglione, V., Ferrari Chen, Y.F., Porcari, A., Canepa, M., Chimenti, C., Di Lenarda, A., Oliva, F., Colivicchi, F., Indolfi, C., Perrone Filardi, P., Cipriani, A., Longhi, S., Cappelli, F., Musca, F., Iacoviello, M., Limongelli, G., Perfetto, F., Merlini, G., et al.. - In: GIORNALE ITALIANO DI CARDIOLOGIA. - ISSN 1827-6806. - 27:2(2026), pp. 141-153. [10.1714/4636.46471]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1779416
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact